MDACC Study No:2006-0200 ( NCT No: NCT00469014)
Title:Busulfan-Fludarabine-Clofarabine with allogeneic stem cell transplantation for advanced refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome and advanced, Gleevec refractory Chronic Myeloid Leukemia. A Randomized Phase II Study.
Principal Investigator:Richard E. Champlin
Treatment Agent:Antithymocyte Globulin; Busulfan; Clofarabine; Fludarabine
Study Status:Terminated
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Advanced Cancers; Blood And Marrow Transplantation
Phase of Study:Phase II
Treatment Agents:Antithymocyte Globulin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:28 days
Supported By:N/A
Return Visit:up to daily for the first 100 days, every 3 months for one year, yearly
thereafter x 5 years
Home Care:none

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Richard E. Champlin
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-792-8750
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults